Latest Asx News

Echo IQ Limited reported a sharp increase in losses for FY25 despite revenue growth, while securing FDA clearance and expanding its AI-driven cardiology platform across major US networks.

ECS Botanics reports a 5% revenue dip to $19.5 million in FY25 but sees strong B2C growth and record harvest volumes, offset by non-cash impairments.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.

Aspermont Limited invites existing shareholders to participate in a $1.25 million Share Purchase Plan at a premium price, supporting its pivot to data-driven intelligence services and a strategic Rio Tinto partnership.

Australian Agricultural Projects Limited reported a $1.96 million profit for FY2025, driven by a strong olive oil harvest despite frost setbacks and rising olive oil prices. The company plans to farm a key orchard section directly after leaseholders declined renewal.

Investor Centre Limited delays its 2025 Annual Report following the liquidation of key funder Amram Corp, triggering a likely trading suspension.

Axiom Properties Limited reports a 55% reduction in net loss for FY25, completing its Glenlea Estate sales and accelerating its Property Technology strategy with a $30 million debt facility for PaySure.

Pengana Global Private Credit Trust (PCX) has delivered a solid first-year performance, achieving an 8.41% total return driven by a 7.04% cash yield and NAV growth. The Trust also increased monthly distributions and declared a special payout, underscoring its commitment to stable income and capital preservation.

Infinity Mining Limited’s 2025 AGM highlighted significant portfolio reshaping, including asset sales and acquisitions, alongside promising exploration results at the Cangai Copper Project.

Prescient Therapeutics has completed a $3 million share placement, bolstering its clinical development programs for innovative cancer treatments including PTX-100 and novel cell therapies.

Spacetalk Ltd reports a successful FY25 transformation with revenue up 12%, losses narrowing by 57%, and a new software-led platform set to fuel scalable subscription growth.

The Hydration Pharmaceuticals Company Limited reported a 55% reduction in half-year losses to $1.44 million, driven by strategic cost reductions and a sharpened focus on US e-commerce operations. Despite a 15% revenue decline, the company is banking on new product launches and retail expansion to fuel growth.